Literature DB >> 17826283

Elution and mechanical properties of antifungal bone cement.

Ben Goss1, Carmen Lutton, Patrick Weinrauch, Majid Jabur, Greg Gillett, Ross Crawford.   

Abstract

The effect of the incorporation of amphotericin B into bone cement was examined; as literature suggests, this may be a feasible method for the treatment of periprosthetic fungal infections. Addition of antifungal increased the compressive strength of the bone cement--a statistically significant amount from 107 +/- 2.3 to 121 +/- 1.5 MPa. Elution of tobramycin and amphotericin B was quantified using ultraviolet-visible spectroscopy. Spectroscopy showed that 18% of the antibiotic was released during the first week, with most released in the first 24 hours. The elution of antifungal, however, was unable to be detected after 1 week, with less than 0.03% released. Amphotericin B does not weaken bone cement. Its inability to be delivered at a clinically significant dose gives no clear indication for its incorporation into cement.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17826283     DOI: 10.1016/j.arth.2006.09.013

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  25 in total

1.  Amphotericin B delivery from bone cement increases with porosity but strength decreases.

Authors:  Chris Kweon; Alex C McLaren; Christine Leon; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2011-11       Impact factor: 4.176

2.  Candidal arthritis in revision knee arthroplasty successfully treated with sequential parenteral-oral fluconazole and amphotericin B-loaded cement spacer.

Authors:  Meng-Huang Wu; Kuo-Yao Hsu
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2010-07-22       Impact factor: 4.342

3.  Staged Reimplantation of a Total Hip Prosthesis After Co-infection with Candida tropicalis and Staphylococcus haemolyticus: A Case Report.

Authors:  Sujeesh Sebastian; Rajesh Malhotra; Ashish Pande; Deepak Gautam; Immaculata Xess; Benu Dhawan
Journal:  Mycopathologia       Date:  2017-07-22       Impact factor: 2.574

4.  Amphotericin B-impregnated bone cement to treat refractory coccidioidal osteomyelitis.

Authors:  Elizabeth S Zhu; George R Thompson; Christopher Kreulen; Eric Giza
Journal:  Antimicrob Agents Chemother       Date:  2013-09-03       Impact factor: 5.191

5.  Liposomal formulation increases local delivery of amphotericin from bone cement: a pilot study.

Authors:  Brian Cunningham; Alex C McLaren; Christine Pauken; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2012-10       Impact factor: 4.176

6.  Are anidulafungin or voriconazole released from polymethylmethacrylate in vitro?

Authors:  Mark S Rouse; Andras Heijink; James M Steckelberg; Robin Patel
Journal:  Clin Orthop Relat Res       Date:  2010-10-21       Impact factor: 4.176

7.  Voriconazole is delivered from antifungal-loaded bone cement.

Authors:  Ryan B Miller; Alex C McLaren; Christine Pauken; Henry D Clarke; Ryan McLemore
Journal:  Clin Orthop Relat Res       Date:  2013-01       Impact factor: 4.176

8.  Econazole-releasing porous space maintainers for fungal periprosthetic joint infection.

Authors:  Alexander M Tatara; Allison J Rozich; Panayiotis D Kontoyiannis; Emma Watson; Nathaniel D Albert; George N Bennett; Antonios G Mikos
Journal:  J Mater Sci Mater Med       Date:  2018-05-11       Impact factor: 3.896

9.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

10.  What is the success of treatment of hip and knee candidal periprosthetic joint infection?

Authors:  Steve W N Ueng; Ching-Yu Lee; Chih-chien Hu; Pang-Hsin Hsieh; Yuhan Chang
Journal:  Clin Orthop Relat Res       Date:  2013-04-30       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.